Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AAPL
6. HOOD
7. QCOM
8. ACN
9. AZN
10. ROIV

Go back to Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
(NASDAQ: NGNE) Delayed: 38.13 -0.47 (1.22%)
Previous Close $38.60    52 Week High $ 
Open $37.79    52 Week Low $ 
Day High $38.75    P/E N/A 
Day Low $36.68    EPS $ 
Volume 228,475